首页> 外文期刊>Journal of cataract and refractive surgery >Alkylphosphocholines for intraocular lens coating
【24h】

Alkylphosphocholines for intraocular lens coating

机译:人工晶状体涂层的烷基磷酸胆碱

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Purpose: To assess the effect of alkylphosphocholine (APC)-coated intraocular lenses (IOLs) on human lens epithelial cell (LEC) proliferation in vitro and the corneal biocompatibility of APC in an organ culture model of human donor eyes. Setting: Research Laboratory for Experimental Ophthalmology, Ludwig-Maximilians-University, Munich, Germany. Design: Experimental study. Methods: Six foldable IOLs differing in optic material were incubated with APC, washed in phosphate-buffered saline, and dried overnight. Intraocular lenses of the same lot served as uncoated controls. Each rehydrated IOL was placed in 1 well of a 24-well plate containing proliferating human LECs. Cell survival was tested by the tetrazolium-dye reduction assay 5 days later. Biocompatibility of the human corneal endothelium was assessed by a 24-hour incubation of human donor corneas with different concentrations of APC before the live/dead assay was performed. Results: Human LEC proliferation was attenuated by APC-coated IOLs (P=.001). Coated hydrophilic acrylic IOLs were more effective inhibitors of human LEC proliferation than coated hydrophobic acrylic or silicone IOLs (P=.001). Alkylphosphocholines were well tolerated by the corneal endothelium in an organ culture model of human donor corneas up to a concentration of 1 mM (n = 12). Conclusions: Results show that APCs are suitable agents for IOL coating without linker molecules. Coated IOLs can inhibit human LEC proliferation and were well tolerated by human donor corneas in organ culture. Financial Disclosure: Dr. Eibl-Lindner holds the patent for "Intraocular lenses treated with alkylphosphocholines for pharmacological aftercataract prophylaxis," international application no. PCT/EP2010/051490. No other author has a financial or proprietary interest in any material or method mentioned. ? 2012 ASCRS and ESCRS Published by Elsevier Inc.
机译:目的:在人供体眼睛的器官培养模型中,评估烷基磷酸胆碱(APC)涂层人工晶状体(IOL)对人晶状体上皮细胞(LEC)增殖的影响以及APC的角膜生物相容性。地点:德国慕尼黑路德维希马克西米利安斯大学实验眼科研究实验室。设计:实验研究。方法:将六个光学材料不同的可折叠IOL与APC孵育,在磷酸盐缓冲液中洗涤,然后干燥过夜。同一批次的人工晶状体用作未涂布的对照。将每个再水合的IOL置于含有增殖的人LEC的24孔板的1孔中。 5天后通过四唑鎓染料还原测定法测试细胞存活。在进行活/死测定之前,通过将人供体角膜与不同浓度的APC孵育24小时,评估人角膜内皮的生物相容性。结果:APC包被的IOL减弱了人LEC的增殖(P = .001)。涂层亲水性丙烯酸IOL比涂层疏水性丙烯酸或有机硅IOL更有效地抑制人LEC增殖(P = .001)。在人类供体角膜的器官培养模型中,浓度高达1 mM(n = 12)的角膜内皮都能很好地耐受烷基磷酸胆碱。结论:结果表明,APC是适用于无接头分子的IOL涂层的试剂。包被的IOL可以抑制人LEC增殖,并且在器官培养中被人供体角膜良好耐受。财务披露:Eibl-Lindner博士拥有“用烷基磷酸胆碱治疗眼内镜以预防药后白内障的药理”的国际专利。 PCT / EP2010 / 051490。其他任何作者都不会在提及的任何材料或方法中拥有财务或所有权利益。 ? 2012年ASCRS和ESCRS,由Elsevier Inc.发行。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号